TY - JOUR
T1 - The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
AU - Parikh, Rahul A.
AU - Wang, Peng
AU - Beumer, Jan H.
AU - Chu, Edward
AU - Appleman, Leonard J.
PY - 2014/6/11
Y1 - 2014/6/11
N2 - MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepa-tocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK) family. HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation (morphogenesis); it plays an important role in normal development and tissue regeneration. The HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with an increased propensity for metastatic disease and poor overall prognosis across multiple tumor types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are under development. This review summarizes the key biological features of the HGF-MET axis, its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are in development.
AB - MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepa-tocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK) family. HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation (morphogenesis); it plays an important role in normal development and tissue regeneration. The HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with an increased propensity for metastatic disease and poor overall prognosis across multiple tumor types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are under development. This review summarizes the key biological features of the HGF-MET axis, its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are in development.
KW - Cancer
KW - HGF inhibitor
KW - MET inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84902313522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902313522&partnerID=8YFLogxK
U2 - 10.2147/OTT.S40241
DO - 10.2147/OTT.S40241
M3 - Review article
AN - SCOPUS:84902313522
SN - 1178-6930
VL - 7
SP - 969
EP - 983
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -
